Related references
Note: Only part of the references are listed.International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Luciano J. Costa et al.
LEUKEMIA (2021)
High-sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events
Ulrike Sommer et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
CD319(SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab
Kah Teong Soh et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use
Kylee H. Maclachlan et al.
PATHOLOGY (2021)
Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
Stuart D. Scott et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters
Michael Keeney et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry
Kah Teong Soh et al.
CLINICS IN LABORATORY MEDICINE (2017)
Flow Cytometry Quality Requirements for Monitoring of Minimal Disease in Plasma Cell Myeloma
Teri A. Oldaker et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Better Therapy Requires Better Response Evaluation: Paving the Way for Minimal Residual Disease Testing for Every Myeloma Patient
Ola Landgren et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Consensus Guidelines on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting
Maria Arroz et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach
Andy C. Rawstron et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Consensus Guidelines for Myeloma Minimal Residual Disease Sample Staining and Data Acquisition
Maryalice Stetler-Stevenson et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Myeloma minimal residual disease testing in the United States: Evidence of improved standardization
Dalia Salem et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Progress and Paradigms in Multiple Myeloma
Kenneth C. Anderson
CLINICAL CANCER RESEARCH (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
Andy C. Rawstron et al.
BLOOD (2015)
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Wen-Chi Yang et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method
Elisabet E. Manasanch et al.
LEUKEMIA & LYMPHOMA (2015)
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
Ola Landgren et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Murielle Roussel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders et al.
BLOOD (2013)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Can we change the disease biology of multiple myeloma?
Ivan Borrello
LEUKEMIA RESEARCH (2012)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry
Samer Z. Al-Quran et al.
HUMAN PATHOLOGY (2007)
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
JF San Miguel et al.
BLOOD (2002)
Share Paper
